Instituto de Reproducción Animal Uruguay, Fundación IRAUy, Montevideo, Uruguay.
Theriogenology. 2011 Apr 15;75(7):1195-200. doi: 10.1016/j.theriogenology.2010.11.030. Epub 2011 Jan 8.
Because intravaginal devices impregnated with 0.3 g of progesterone (i.e., CIDR-G) contain remaining hormone after their use in a Short-term Protocol (5 to 7 d of treatment), the reuse of these devices is proposed in goats. Two experiments were designed to study the effects of the reutilization of CIDR-G, establishing serum progesterone concentrations, follicular development, ovulatory response, and fertility. Experiment 1: Thirty dairy goats received a Short-term Protocol for 5 d using CIDR-G of first use (new devices, n = 10), second use (previously used for 5 d, n = 10), or third use (previously used twice for 5 d each time, n = 10). Goats were given (im) prostaglandin F(2α) (10 mg dinoprost) and eCG (300 IU) at device insertion and withdrawal, respectively. Serum progesterone concentrations induced by CIDR-G of first use were higher than CIDR-G of second or third use (P < 0.05); concentrations were consistently > 1 ng/mL in all females treated with reused devices. Estrus and ovulation were synchronized in 100% of goats (no differences among treatments). All females treated with new devices, but only 80% of females treated with re-used devices ovulated a new follicle that emerged after CIDR-G insertion (P = NS). Ovulation occurred between 60 and 70 h after device removal (no differences among groups). Experiment 2: In goats subjected to a Short-term Protocol followed by AI at 54 h after CIDR-G, pregnancy rates with CIDR-G of first, second, and third use were 75.3% (64/85), 67.4% (60/89), and 62.1% (54/87), respectively (devices of first versus third use, P < 0.05). In summary, intravaginal devices originally containing 0.3 g of progesterone appeared effective to synchronize estrus and ovulation after first, second and third use in the Short-term Protocol. Although the pregnancy rate with reused devices was acceptable (i.e., > 60%), it was significantly lower than that achieved with new devices and further studies to ensure adequate follicular turnover are required.
由于阴道内装置（CIDR-G）中含有 0.3 克孕激素，在短期程序（5-7 天治疗）中使用后仍有剩余激素，因此在山羊中提出了重复使用这些装置的建议。本研究设计了两项实验，以研究 CIDR-G 重复使用对血清孕激素浓度、卵泡发育、排卵反应和生育力的影响。实验 1：30 只奶牛山羊接受短期程序治疗 5 天，使用 CIDR-G 首次使用（新装置，n = 10）、第二次使用（之前使用 5 天，n = 10）或第三次使用（之前使用两次，每次 5 天，n = 10）。山羊在装置插入和取出时分别给予（im）前列腺素 F2α（10mg 地诺前列酮）和 eCG（300IU）。首次使用 CIDR-G 诱导的血清孕激素浓度高于第二次或第三次使用（P < 0.05）；所有使用重复使用装置的雌性动物的浓度均持续 > 1ng/mL。100%的山羊发情和排卵同步（处理之间无差异）。所有使用新装置的雌性动物都排卵，但只有 80%使用重复使用装置的雌性动物排卵了新卵泡，该卵泡在 CIDR-G 插入后出现（P = NS）。排卵发生在装置取出后 60-70 小时（组间无差异）。实验 2：在接受短期程序治疗并在 CIDR-G 后 54 小时进行 AI 的山羊中，CIDR-G 首次、第二次和第三次使用的妊娠率分别为 75.3%（64/85）、67.4%（60/89）和 62.1%（54/87）（装置首次与第三次使用，P < 0.05）。总之，阴道内装置最初含有 0.3 克孕激素，在短期程序中首次、第二次和第三次使用时，对发情和排卵同步具有有效性。尽管重复使用装置的妊娠率可接受（即>60%），但明显低于新装置的妊娠率，需要进一步研究以确保充分的卵泡周转。
